Qin Wang, M.D., Ph.D.
Neuropharmacology
Augusta University
Recruited: 2022
Qin Wang studies how receptors on the surface of brain cells pass along chemical signals, and how those signals malfunction in Alzheimer's disease, epilepsy and post-traumatic stress.
Wang’s work in Alzheimer’s is especially significant. Two proteins in the brain, beta-amyloid and tau, are behind the havoc that brings on Alzheimer’s. The prevailing hypothesis holds that beta-amyloid triggers tau, which toxifies neurons and ultimately kills cells; it’s a sequence that’s been likened to the firing of a gun. Why and how this sequence happens has been a mystery, and Wang is helping to solve it.
Much of her research centers on norepinephrine, a brain chemical involved in alertness and memory. The brain's norepinephrine system is damaged early in Alzheimer's, and Wang has tied one of its receptors to both of the disease's toxic proteins, beta-amyloid and tau. Importantly, several of Wang’s studies evaluate how drugs already approved for other conditions can be used to treat Alzheimer’s. Some have even protected the brain in mice from the disease.
Wang is the inaugural director of the Program for Alzheimer's Therapeutics Discovery at the Medical College of Georgia at Augusta University. She joined in 2022 from the University of Alabama at Birmingham.
Research
- Linked a norepinephrine receptor to both of Alzheimer's toxic proteins. Alzheimer's is marked by clumps of beta-amyloid and tangles of tau. Wang showed that a norepinephrine receptor called alpha-2A plays a part in both proteins. Activating this receptor pushed brain cells to make more beta-amyloid, but removing it lowered the amount. Beta-amyloid, in turn, latched onto the receptor and redirected its signal toward an enzyme that drives harmful changes in tau. On its own, beta-amyloid can switch on this enzyme only at high levels. Acting through the norepinephrine receptor, it did so at levels 50 to 100 times lower.
- Opened a route to raising a protective Alzheimer's protein with an existing drug. SORLA, a protein that limits how much amyloid the brain makes, is low in people with Alzheimer's, and there was no known drug to raise it. Wang's team found the signals that mark SORLA for destruction. Blocking them with auranofin, a rheumatoid arthritis drug, raised SORLA, cut amyloid and improved cognition in mice. It also lowered amyloid in neurons grown from stem cells of people with Alzheimer's.
- Connected a common prostate cancer treatment to brain inflammation that worsens cognitive decline. Androgen deprivation therapy, a hormone-lowering treatment for prostate cancer, is linked to higher dementia risk, for reasons that were unknown. In mice with prostate tumors and Alzheimer's-like disease, Wang's team found the therapy weakens the blood-brain barrier, letting immune cells infiltrate and inflame the brain and speeding cognitive decline. Natalizumab, a multiple sclerosis drug that blocks this infiltration, improved cognition.
- Designed a brain-targeted way to strengthen the body's own seizure brake. The brain halts seizures partly through adenosine acting on a receptor called A1, but drugs that activate A1 cause side effects because the receptor is found throughout the body. Wang developed a peptide that strengthens A1’s response to the brain's own adenosine by blocking its tie to a partner protein found in nerve cells. Given as a nasal spray, it reduced epileptic activity in mice with Alzheimer's-like disease.
Choosing Georgia
“When I came to visit Augusta University, I saw tremendous enthusiasm for this new program in Alzheimer’s Disease research. Everyone is really determined to push things forward, and the faculty are very collaborative and enthusiastic.”
Industry Relations
OUTSIDE THE LAB
Wang serves on the scientific advisory board of Terran Biosciences, a company developing treatments for neurological and psychiatric diseases. She and her Augusta University colleague, Kai Jiao, are co-founders of BioQure, LLC.
SELECT HONORS
- Chair of Neuropharmacology Division and member Executive Committee, American Society for Pharmacology and Experimental Therapeutics
- Associate Editor, Current Alzheimer’s Research (peer-reviewed journal) – 2023-present
- Associate Editor, Brain Science – 2022-present
- Associate Editor, Frontiers in Neuroscience – 2021-present
